BCM
TMBR

Bridgeway Capital Management’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Bridgeway Capital Management’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,102
Closed -$96K – 1348
2021
Q3 		$96K Hold
2,102
– – ﹤0.01% 1253
2021
Q2 		$128K Buy
2,102
+1,092
+108% +$76.7K ﹤0.01% 1299
2021
Q1 		$103K Sell
1,010
-2,156
-68% -$186K ﹤0.01% 1328
2020
Q4 		$118K Hold
3,166
– – ﹤0.01% 1255
2020
Q3 		$157K Buy
+3,166
New +$255K ﹤0.01% 1209

Other funds holding TMBR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bridgeway Capital Management's TMBR Position: Q4 2021 in Review

Bridgeway Capital Management sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2021, closing a stake of 2,102 shares — an estimated $96K sold.

Bridgeway Capital Management first reported a position in TMBR in Q3 2020 and held it in 5 quarters. The position peaked at $157K in Q3 2020. 17 funds tracked by Wall St. Rank hold TMBR as of Q4 2021.

  • Bridgeway Capital Management reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 2,102 Timber Pharmaceuticals, Inc. shares in Q4 2021, an estimated $96K.
  • Bridgeway Capital Management first reported a position in Timber Pharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
  • Bridgeway Capital Management's Timber Pharmaceuticals, Inc. position peaked at $157K in Q3 2020.
  • 17 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2021.

Based on Bridgeway Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.